A 13% reduction in the risk of cardiovascular events is statistically significant but not spectacular.
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.